Update on Spinal Cord Injury Management.
Journal
Clinical spine surgery
ISSN: 2380-0194
Titre abrégé: Clin Spine Surg
Pays: United States
ID NLM: 101675083
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
3
4
2020
medline:
12
10
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
The management of acute spinal cord injury requires a multidisciplinary approach to maximize patient outcomes and potential. Treatment of this injury involves both surgical and medical intervention. Medical intervention in acute spinal cord injury is aimed at decreasing the neurotoxic environment that occurs as part of the secondary injury. New neuroregenerative therapies are being developed.
Identifiants
pubmed: 32235169
doi: 10.1097/BSD.0000000000000956
pii: 01933606-202008000-00002
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
258-264Références
National Spinal Cord Injury Statistical Center (NSCISC). Facts and Figures at a Glance 2014. 2014. Available at: www.nscisc.uab.edu/. Accessed October 2, 2018.
Ahuja CS, Nori S, Tetreault L, et al. Traumatic spinal cord injury—repair and regeneration. Neurosurgery. 2017;80(3S):S9–S22.
Ahuja CS, Martin AR, Fehlings M. Recent advances in managing a spinal cord injury secondary to trauma. F1000Res. 2016;5:1–13.
Bhanot Y, Rao S, Ghosh D, et al. Autologous mesenchymal stem cells in chronic spinal cord injury. Br J Neurosurg. 2011;25:516–522.
Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. N Engl J Med. 1990;322:1405–1411.
Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev. 2012;1:CD001046.
Casha S, Zygun D, McGowan MD, et al. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain. 2012;135:1224–1236.
Dvorak MF, Noonan VK, Fallah N, et al. The influence of time from injury to surgery on motor recovery and length of hospital stay in acute traumatic spinal cord injury: an observational Canadian cohort study. J Neurotrauma. 2015;32:645–654.
Hawryluk G, Whetstone W, Saigal R, et al. Mean arterial blood pressure correlates with neurological recovery after human spinal cord injury: analysis of high frequency physiologic data. J Neurotrauma. 2015;32:1958–1967.
Martin ND, Kepler C, Zubair M, et al. Increased mean arterial pressure goals after spinal cord injury and functional outcome. J Emerg Trauma Shock. 2015;8:94.
Kamiya K, Koda M, Furuya T, et al. Neuroprotective therapy with granulocyte colony-stimulating factor in acute spinal cord injury: a comparison with high-dose methylprednisolone as a historical control. Eur Spine J. 2015;24:963–967.
Kepler CK, Schroeder GD, Martin ND, et al. The effect of preexisting hypertension on early neurologic results of patients with an acute spinal cord injury. Spinal Cord. 2015;53:763–766.
Fehlings MG, Vaccaro A, Wilson JR, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PloS One. 2012;7:e32037.
Wilson J, Singh A, Craven C, et al. Early versus late surgery for traumatic spinal cord injury: the results of a prospective Canadian cohort study. Spinal Cord. 2012;50:840–843.
Ito Y, Sugimoto Y, Tomioka M, et al. Does high dose methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury? A prospective study about neurological recovery and early complications. Spine. 2009;34:2121–2124.
Aomar MM, Cortiñas MS, Delgado JT, et al. Assessment of neurologic function and complications in a retrospective cohort of patients with acute spinal cord injury due to trauma treated with large-dose methylprednisolone. Rev Esp Anestesiol Reanim. 2011;58:583–588.
Chikuda H, Yasunaga H, Takeshita K, et al. Mortality and morbidity after high-dose methylprednisolone treatment in patients with acute cervical spinal cord injury: a propensity-matched analysis using a nationwide administrative database. Emerg Med J. 2013;31:201.
Khan MF, Burks SS, Al-Khayat H, et al. The effect of steroids on the incidence of gastrointestinal hemorrhage after spinal cord injury: a case-controlled study. Spinal Cord. 2014;52:58.
Evaniew N, Noonan VK, Fallah N, et al. Methylprednisolone for the treatment of patients with acute spinal cord injuries: a propensity score-matched cohort study from a Canadian multi-center spinal cord injury registry. J Neurotrauma. 2015;32:1674–1683.
Sunshine JE, Dagal A, Burns SP, et al. Methylprednisolone therapy in acute traumatic spinal cord injury: analysis of a regional spinal cord model systems database. Anesth Analg. 2017;124:1200–1205.
Bracken MB, Collins WF, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA. 1984;251:45–52.
Bracken MB, Holford TR. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg. 1993;79:500–507.
Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the third national acute spinal cord injury randomized controlled trial. JAMA. 1997;277:1597–1604.
Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury—a randomized, placebo-controlled trial with GM-1 ganglioside. New Engl J Med. 1991;324:1829–1838.
Imanaka T, Hukuda S, Maeda T. The role of GM1-ganglioside in the injured spinal cord of rats: an immunohistochemical study using GM1-antisera. J Neurotrauma. 1996;13:163–170.
Geisler FH, Coleman WP, Grieco G, et al. The Sygen® multicenter acute spinal cord injury study. Spine. 2001;26(24S):S87–S98.
Fehlings MG, Nakashima H, Nagoshi N, et al. Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial. Spinal Cord. 2016;54:8–15.
Grossman RG, Fehlings MG, Frankowski RF, et al. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma. 2014;31:239–255.
Simard JM, Tsymbalyuk O, Keledjian K, et al. Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. Exp Neurol. 2012;233:566–574.
Wu Y, Satkunendrarajah K, Teng Y, et al. Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. J Neurotrauma. 2013;30:441–452.
Festoff BW, Ameenuddin S, Arnold PM, et al. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem. 2006;97:1314–1326.
Yoon SH, Shim YS, Park YH, et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. Stem Cells. 2007;25:2066–2073.
Nishio Y, Koda M, Kamada T, et al. Granulocyte colony-stimulating factor attenuates neuronal death and promotes functional recovery after spinal cord injury in mice. J Neuropathol Exp Neurol. 2007;66:724–731.
Takahashi H, Yamazaki M, Okawa A, et al. Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I/IIa clinical trial. Eur Spine J. 2012;21:2580–2587.
Kamiya K, Koda M, Furuya T, et al. Neuroprotective therapy with granulocyte colony-stimulating factor in acute spinal cord injury: a comparison with high-dose methylprednisolone as a historical control. Eur Spine J. 2014;24:963–967.
Tan H, Zhong Y, Cheng Y, et al. Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage. Int J Ophthalmol. 2011;4():652–657.
Fehlings MG, Theodore N, Harrop J, et al. A phase I/IIa clinical trial of a recombinant rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011;28:787–796.
Taylor N. Vertex Halts Phase 2b Spinal Injury Trial for Futility. FierceBiotech, 2018. Available at: www.fiercebiotech.com/biotech/vertex-halts-phase-2b-spinal-injury-trial-for-futility. Accessed December 1, 2018.